University of Rochester Medical Center-James P. Wilmot Cancer Center, Rochester, NY
Carla Casulo , Melissa C. Larson , Jonathan R Day , Thomas Matthew Habermann , Izidore S. Lossos , Yucai Wang , Loretta J. Nastoupil , Christopher Strouse , Dai Chihara , Peter Martin , Jonathon Brett Cohen , Brad S. Kahl , Jia Ruan , Walter Richard Burack , Jean Louise Koff , Jonathan W. Friedberg , James Robert Cerhan , Christopher Flowers , Brian K. Link , Matthew J. Maurer
Background: While most patients (pts) with follicular lymphoma (FL) usually have favorable outcomes, those with refractory disease after first-line anti-CD20 based immunochemotherapy (IC), or progression within 24 months of diagnosis (POD24) have higher risk of premature death. There are no standard approaches for treating this vulnerable group and studies testing novel agents are ongoing in this setting. We sought to investigate clinical practice treatment choices and efficacy for pts with POD24 that align with eligibility criteria for the randomized SWOG1608 which compares IC with novel agents in this population. Methods: This was a multicenter observational cohort study from the LEO Consortium. Eligible pts had grade 1-3a FL diagnosed between 1/1/2002 and 2/1/2019, and initiated therapy after POD24 to first-line bendamustine or CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone) based IC. Observation, radiotherapy, or rituximab monotherapy were permitted prior to IC and pts with transformation prior to the subsequent therapy after IC were excluded as per S1608. Outcomes of interest were overall and complete response rate (ORR/CR), progression-free survival (PFS), and overall survival (OS). Results: We identified 196 eligible pts with early progression to IC (39% antiCD20 Benda; 61% antiCD20 CHOP) who received subsequent therapy. Median age at post IC treatment was 57 years, 78% grade 1-2 FL. Treatments for pts with POD24 included CHOP- or Benda-based in 31%, salvage/hematopoietic stem cell transplant (HSCT) in 27%, novel therapies in 10% (including phosphatidylinositol 3-kinase inhibitors), antiCD20 monotherapy in 9%, and lenalidomide-based treatment in 8% (table); 21% of pts were treated on clinical trials. Across all treatments, ORR (CR) was 63% (37%) (95% CI: 55-70). At a median follow up of 6.2 years, 2 year PFS was 22% (95% CI: 17%-29%) and 5 year OS was 71% (95% CI: 65-79). Outcomes by regimen are shown in the table. Conclusions: Pts with FL experiencing POD24 following first-line IC are treated heterogeneously, with many pts still receiving IC as subsequent therapy. Despite modest CR rates and low 2-year PFS, 5-year OS appear to be improving compared to historical outcomes. This supports the ongoing need to investigate novel treatments in this population.
Post POD24 therapy (%) | ORR (95%CI)/CR % | 2 yr PFS % (95%CI) | 5 yr OS % |
---|---|---|---|
HSCT (27) | 59 (44-72)/40 | 23 (14-37) | 67 (56-81) |
CHOP +/- Anti CD20 (18) | 58 (39-75)/29 | 20 (10-40) | 66 (51-86) |
Benda +/- AntiCD20 (13) | 85 (61-96)/55 | 27 (14-51) | 83 (70-100) |
Novel therapy (10) | 50 (29-71)/17 | 10 (3-37) | 84 (65-100) |
AntiCD20 monotherapy (9) | 59 (34-81)/35 | 38 (20-69) | 73 (53-100) |
Lenalidomide based (8) | 73 (45-91)/53 | 27 (12-65) | 75 (54-100) |
Other chemo (7) | 77 (46-94)/23 | 8 (1-54) | 76 (55-81) |
Radioimmunotherapy (6) | 50 (24-76)/30 | 18 (5-64) | 46 (22-93) |
Non systemic (2) | 100 (6-100)/100 | 33 (7-100) | 100 (100-100) |
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Abstract Disclosures
2023 ASCO Annual Meeting
First Author: David Lavie
2023 ASCO Annual Meeting
First Author: Ian W. Flinn
2021 ASCO Annual Meeting
First Author: Laurie Helen Sehn
2015 ASCO Annual Meeting
First Author: Nathan Hale Fowler